Seeking Alpha

GlaxoSmithKline (GSK) continues to looks outside to spur innovation, investing €17.5M in a...

GlaxoSmithKline (GSK) continues to looks outside to spur innovation, investing €17.5M in a new venture fund that will provide backing for drugs that treat rare diseases. The fund, called Kurma Biofund II, is quite small, having raised just €44M to date, which may not be enough to take early stage companies into major trials. GSK's investment adds to a $495M deal it struck with Avalon Ventures to finance start-ups.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|